EcoDrugPlus

Endothelin Receptor Type A

Ensembl ID : ENSHCOG00000005641
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSHCOG00000002794
Gene Symbol: EDNRB
3 Cross references
195 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSHCOG00000001287
Gene Symbol: EZH2
3 Cross references
229 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSHCOG00000017284
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSHCOG00000002391
Gene Symbol: LOC109510200
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSHCOG00000017162
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSHCOG00000003429
Gene Symbol: ERBB3
3 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSHCOG00000008801
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSHCOG00000009913
Gene Symbol: ERBB4
3 Cross references
230 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSHCOG00000014381
Gene Symbol: ESR1
3 Cross references
215 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSHCOG00000020638
Gene Symbol: LOC109520327
3 Cross references
210 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSHCOG00000009584
Gene Symbol: LOC109516302
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).